Each day another damning detail emerges about President Obama’s deliberate assault on every facet of America’s institutions and the potentially dire effects on Americans. With the burgeoning host of diseases now entering the U.S., courtesy of Barack Hussein Obama, what impact does this onslaught have on the blood supply and its quality? Let’s consider the witch’s brew now facing America’s health care system.
Judicial Watch uncovered Obama’s stealth operation to “actively formulate plans to admit Ebola-infected non-U.S. citizens into the United States for treatment within the first days of diagnosis.” Yet it is “unclear who would bear the high costs of transporting and treating non-citizen Ebola patients.” In fact, “the plans include special waivers of laws and regulations that ban the admission of non-citizens with a communicable disease as dangerous as Ebola.”
Bryan Preston notes that the Morbidity and Mortality Weekly Report or MMWR, “is the Centers for Disease Control’s premiere journal for reporting and tracking infectious diseases in the United States.” And, yet, the MMWR for the week ending October 4, 2014 made no mention of the Ebola case in Dallas. Puzzling, indeed, since Ebola is a viral hemorrhagic fever and the CDC specifically lists it as a notifiable disease in a 2010 report.
And as we have come to expect from the least transparent administration, the “Obama administration has shunned multiple requests to respond to the report exposing its secret plan to admit Ebola infected foreigners into the United States.”
Then there are the illegals coming from Mexico, Honduras, Guatemala and El Salvador with their myriad collection of diseases, many of which have not been encountered in this country. Dengue fever occurs in Central and South America and has led to 1/2 million hospitalizations and 25,000 deaths. According to Winton Gibbons in his article entitled “Blood Screening/Transfusion Future Product Market Concepts” of September 2013, “[o]nly 13% of low income countries have a national hemovigilance system to monitor and improve safe blood transfusion.”
Which brings me to Dengue fever. Dengue is endemic in more than 110 countries. According to a June 2011 article entitled “Dengue antibodies in blood donors,” the authors conclude that “the results of the current analysis show that the introduction of quantitative or molecular serological methods to determine the presence of anti-dengue antibodies or the detection of the dengue virus in blood donors…should be established so that the quality of blood transfusions is guaranteed.” And while the authors assert that “the current research suggests that blood donors were not actively infected with the dengue virus…it is well known that methodologies for virus detection also include the more efficient viral RNA and NSI antigen investigations for the dengue virus which eliminate the immunological window period. The current study may not have identified anti-dengue IgM antibodies [.]” It should be noted that while a testing kit has been produced that can identify Dengue within 15 minutes at an 80 percent success rate, there is no vaccine available for Dengue Fever.